@entity6 @entity35 display exaggerated @entity1931 behavior in response to noxious stimuli that may model aspects of @entity3949 . This study examined the contribution of spinal @entity3009 production to this exaggerated @entity1931 behavior. @entity35 were implanted with spinal dialysis probes and received noxious stimulation to the hind paw by subcutaneous injection of 0.5% @entity406 solution. @entity1421 ( @entity1421 ) was measured in dialysates of lumbar spinal cerebrospinal fluid concurrent with behavioral responses to @entity406 injection. In separate experiments, @entity406 -evoked behavioral responses were measured after intrathecal delivery of either a cyclooxygenase inhibitor or an EP(1) receptor antagonist, and cyclooxygenase protein was measured in spinal cord homogenates. @entity6 @entity35 exhibited exaggerated behavioral responses to paw @entity406 injection and a concurrent prolongation of @entity406 -evoked @entity1421 release. @entity406 -evoked behavioral responses were dose-dependently reduced in @entity6 @entity35 by spinal delivery of a cyclooxygenase inhibitor or an EP(1) receptor antagonist. Protein levels of @entity4645 were elevated in the spinal cord of @entity6 @entity35 , whereas @entity25883 protein was reduced. @entity146 in @entity6 @entity35 is associated with both increased @entity4645 protein and cyclooxygenase-mediated @entity1421 release. Spinal delivery of selective inhibitors of @entity4645 or antagonists of @entity3009 receptors may have therapeutic potential for treating @entity3949 .

Elevated spinal cyclooxygenase and @entity3009 release during XXXX in @entity6 @entity35 .

@entity1931 :: ('MESH:D006930', 'Disease') :: ['hyperalgesic'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetic', 'diabetic'] @entity146 :: ('MESH:D001523', 'Disease') :: ['Hyperalgesic behavior'] @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE(2)', 'Prostaglandin E(2)'] @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin', 'Formalin'] @entity3949 :: ('MESH:D003929', 'Disease') :: ['painful diabetic neuropathy'] @entity3009 :: ('CHEBI:26333', 'Chemical') :: ['prostaglandin'] @entity25883 :: ('24693(Tax:10116)', 'Gene') :: ['cyclooxygenase-1'] @entity35 :: ('10116', 'Species') :: ['Rats', 'rats'] @entity4645 :: ('29527(Tax:10116)', 'Gene') :: ['cyclooxygenase-2']
@entity1931 :: (MESH:D006930,Disease) :: ['hyperalgesia']
